This article was originally published on Targeted Oncology The multiple myeloma treatment paradigm has seen an assortment of therapeutic advances in recent years with agents that have demonstrated the ability to extend survival in patients and improving disease outcomes. However, the severity of the disease continues to linger without a cure, calling for oncologists to...Continue Reading
This article was originally published on The Limbic The anti-CD38 mAb daratumumab (Darzalex) has received a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) for PBS listing as a second line treatment in combination with bortezomib and dexamethasone for patients with multiple myeloma. The drug was recommended on the basis that it should be available...Continue Reading
This article was originally posted on Strathroy Age Dispatch Multiple myeloma was practically a death sentence when Joanne Ternovan was diagnosed. Like many people who had this incurable cancer of the plasma cells, she was given three years to live. That was 22 years ago. “I didn’t think I was going to make it this...Continue Reading
This article was originally published on TB Newswatch.com THUNDER BAY – Jerry Vanderwey went through months of unexplained rib and back pain before discovering the cause was multiple myeloma, a blood cancer, back in 2012. He hoped Sunday’s Multiple Myeloma March at Prince Arthur’s Landing would grow awareness of the disease so others might flag...Continue Reading
This was originally published by News Medical Life Sciences By combining genomic testing and next generation sequencing technology, a new partnership led by RCSI researchers aims to advance predictive tests for multiple myeloma (MM), the second most common blood cancer in Ireland. The study will be carried out at Beaumont Hospital Dublin and run through...Continue Reading
Dr. Richard E. Stein, Chairman of the Crohn’s & Colitis NZ Charitable Trust, has asked for our support to help share their petition for funding of a desperately needed medication. Their petition asks for funding for a medication called ustekinumab (Stelara) that has been funded in Australia since 2015 and in 37 other countries around the...Continue Reading
DREAMM 7 – A Multicentre, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belnatamab mafadotin (GSK2857916), Bortezomib, and Dexamethasone Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma Recruitment to start from end of September (Phase III study from GSK) Information and how to...Continue Reading
This post was originally published by Cure Specific disease characteristics of, and treatments for, multiple myeloma were not associated with increased mortality risk in patients with multiple myeloma who developed COVID-19, according to data published in Journal of Hematology & Oncology. “Limited studies describing the impact of COVID-19 both in the (United States) and abroad suggest...Continue Reading
This post was originally published by Targeted Oncology C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses what is next for chimeric antigen receptor (CAR) T-cell therapy in the multiple myeloma landscape. Landgren thinks the field is about to reach its potential since there are several...Continue Reading
This article was originally published by OncLive In just the past 5 years, incredible progress has been made in multiple myeloma, evidenced by the emergence of novel CD38 antibodies, BCMA-directed treatments, and cereblon E3 ligase modulators (CELMoDs), according to Thomas G. Martin, MD. “We have a lot of options that are coming up. It’s really...Continue Reading
